GlassScriptPhysician profile
Trisha P Larkin
NPI 1093125403
$4,412.69
in general payments reported to CMS, 2019-2025
12 companies · $694 in 2025
The $694 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2022: $19.14 · 2023: $338 · 2024: $3,249 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,543 · Food and Beverage: $1,583 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,542.50 |
| Food and Beverage | $1,582.94 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Day One Biopharmaceuticals | $2,628.94 | 2024-2025 | Ojemda |
| Alexion Pharmaceuticals, INC. | $615.20 | 2023-2025 | Koselugo, Ultomiris |
| Jazz Pharmaceuticals INC. | $535.91 | 2019-2025 | |
| Astellas Pharma US INC | $198.58 | 2024 | Cresemba |
| Servier Pharmaceuticals LLC | $139.64 | 2023 | |
| Novartis Pharmaceuticals Corporation | $94.60 | 2023-2024 | |
| Springworks Therapeutics, INC. | $69.28 | 2025 | Gomekli |
| Pfizer INC. | $46.90 | 2024 | |
| Agios Pharmaceuticals, INC. | $22.03 | 2025 | Pyrukynd |
| Genentech, INC. | $21.98 | 2024 | Hemlibra |
| Genzyme Corporation | $20.49 | 2024 | |
| Janssen Scientific Affairs, LLC | $19.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Larkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.